Trial reportDrugs1987
Human insulin. A review of its biological activity, pharmacokinetics and therapeutic use.
Trial report in Drugs, 1987. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- 'Human' insulin versus animal insulin in people with diabetes mellitus.The Cochrane database of systematic reviews · 2005 · on this mapPooled it
- Insulin disposition in the lung following oral inhalation in humans : a meta-analysis of its pharmacokinetics.Clinical pharmacokinetics · 2004Pooled it
- Computational formulation study of insulin on biodegradable polymers.RSC advances · 2023Article
- Counteractive Effects of Choline Geranate (CAGE) ILs and Ethanol on Insulin's Stability-A Leap Forward towards Oral Insulin Formulation.Molecules (Basel, Switzerland) · 2022Article
- An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.Ophthalmology and therapy · 2022Review
- Emerging Nano- and Micro-Technologies Used in the Treatment of Type-1 Diabetes.Nanomaterials (Basel, Switzerland) · 2020Review
- Recombinant Human Insulins - Clinical Efficacy and Safety in Diabetes Therapy.European endocrinology · 2016Review
- Equivalent Recombinant Human Insulin Preparations and their Place in Therapy.European endocrinology · 2015Review
- Polymeric nanoparticle drug delivery technologies for oral delivery applications.Expert opinion on drug delivery · 2015Review
- Polymeric nanoparticle technologies for oral drug delivery.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2014Review
- Recent advances in protein and Peptide drug delivery: a special emphasis on polymeric nanoparticles.Protein and peptide letters · 2014Review
- Encapsulated islets transplantation: Past, present and future.World journal of gastrointestinal pathophysiology · 2012Article
- Pharmacokinetic considerations of new insulin formulations and routes of administration.Clinical pharmacokinetics · 1997Review
- Article
- Insulin use in pregnancy. Clinical pharmacokinetic considerations.Clinical pharmacokinetics · 1993Review
- The pharmacokinetics of pulmonary-delivered insulin: a comparison of intratracheal and aerosol administration to the rabbit.Pharmaceutical research · 1992Article
- Insulin induces changes in the subcellular distribution of actin and 5'-nucleotidase.Molecular and cellular biochemistry · 1991Article
- Management of diabetic ketoacidosis.Drugs · 1989Review
- Recent advances in nanotechnology for diabetes treatment.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human insulin, whether produced by recombinant DNA techniques (biosynthetic, insulin crb) or enzymatic modification of porcine insulin (semisynthetic, insulin emp) is equivalent in biological activity to porcine insulin following intravenous administration. Slight differences between human and porcine insulin in hypoglycaemic activity after subcutaneous injection appear to be related to differences in absorption, and are unlikely to be of major clinical importance. Similarly, reported minor differences in counterregulator hormone response to human insulin compared with porcine insulin need further study, but they are unlikely to have important clinical implications. In clinical use the therapeutic efficacy of human insulin is similar to that of porcine insulin. The lower antigenicity with human insulin relative to purified porcine insulin is of potential therapeutic value, and it is logical to use human insulin in newly diagnosed diabetics, in patients treated intermittently with insulin, in cases of immunological insulin resistance, and in patients with allergy and local reaction against animal insulin. Thus, human insulin seems to have no disadvantages compared with purified porcine insulin and may have some advantages. While there appears to be no compelling reason to change patients whose diabetes is presently well controlled with purified porcine insulin to human insulin, the availability of human insulin at a price equal to or less than that of animal origin makes such a change logical. In the meantime, human insulin should be considered the insulin of 'first choice' for newly diagnosed diabetics requiring insulin therapy and in carbohydrate intolerance and diabetes occurring during pregnancy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.